Carbonic anhydrase inhibitors show potential in reducing tau protein buildup, offering new therapeutic avenues for neurodegenerative diseases like tauopathies.

They discovered that drugs known as carbonic anhydrase inhibitors—of which the glaucoma drug methazolamide is one—clear tau ...

Researchers have discovered that methazolamide, a glaucoma drug, can clear tau protein build-up in the brain, a key factor in dementias like Alzheimer's. This study, using zebrafish and mice models, s ...

So, how might this drug clear these protein clumps? Methazolamide is a type of drug known as a carbonic anhydrase inhibitor, which stops the activity of an important enzyme involved in regulating ...

If this is indeed their biological function, it would represent the first documented Cu-based carbonic anhydrase. The ...

Glaucoma drug methazolamide shows potential in fighting neurodegenerative diseases, offering new hope for treating conditions ...

Researchers in the UK Dementia Research Institute at the University of Cambridge in the UK focussed on a class of drugs known ...

1 Prostate-specific membrane antigen. 2 Carbonic anhydrase IX. 3 TLX102 labelled with astatine-211. All other listed alpha therapies labelled with actinium-225. 4 Large amino acid transporter 1. 5 ...

Based on drug class, the glaucoma therapeutics market is segmented into beta blockers, alpha-adrenergic agonists, prostaglandins analogs, carbonic anhydrase inhibitors, combination drugs, and others.

According to a new comprehensive report from The Insight Partners, the global Glaucoma Therapeutics Market is experiencing significant growth owing to ...